福元医药：取得注册证，产品名称为“吡格列酮二甲双胍片”

Core Viewpoint - Fuyuan Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its product "Pioglitazone Metformin Tablets," allowing the company to commence production [1] Company Summary - Fuyuan Pharmaceutical's revenue composition for the year 2024 is as follows: 93.12% from pharmaceutical preparations, 6.46% from medical devices, 0.36% from other businesses, and 0.06% from other sources [1] - As of the report date, Fuyuan Pharmaceutical has a market capitalization of 11.2 billion yuan [1]